INT256227

From wiki-pain
Revision as of 01:24, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 2.92
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (EDN1, VEGFA) extracellular region (EDN1, VEGFA) cytoplasm (EDN1, VEGFA)
growth (VEGFA) proteinaceous extracellular matrix (VEGFA) cell-cell signaling (EDN1)
EDN1 (Homo sapiens)
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 4 70.76 Quite High
Brush evoked pain 2 65.44 Quite High
diabetic neuropathy 8 41.56 Quite Low
tolerance 6 37.28 Quite Low
ischemia 6 32.56 Quite Low
Inflammation 4 5.00 Very Low Very Low Very Low
antagonist 4 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetic Retinopathy 12 98.56 Very High Very High Very High
Diabetes Mellitus 106 95.40 Very High Very High Very High
Injury 4 75.68 Quite High
Peripheral Neuropathy 6 70.76 Quite High
Neuropathic Pain 14 65.44 Quite High
Nociception 2 62.12 Quite High
Increased Venous Pressure Under Development 34 55.24 Quite High
Congenital Anomalies 2 52.80 Quite High
Diabetic Angiopathy 26 49.20 Quite Low
Impaired Glucose Tolerance 6 37.28 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An interaction between ET-1 and vascular endothelial growth factor (VEGF) has also been reported, and some positive results of treatment with endothelin receptor blockers have raised interest in these substances as potentially therapeutic agents (Masuzawa et al 2006).
ET-1 Binding (interaction) of vascular endothelial growth factor
1) Confidence 0.18 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 1.46 Pain Relevance 0.13
An interaction between ET-1 and vascular endothelial growth factor (VEGF) has also been reported, and some positive results of treatment with endothelin receptor blockers have raised interest in these substances as potentially therapeutic agents (Masuzawa et al 2006).
ET-1 Binding (interaction) of VEGF
2) Confidence 0.18 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 1.46 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox